124 related articles for article (PubMed ID: 21955798)
1. Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations.
Rozen P; Liphshitz I; Barchana M
Eur J Cancer Prev; 2012 May; 21(3):247-53. PubMed ID: 21955798
[TBL] [Abstract][Full Text] [Related]
2. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
Vilkin A; Rozen P; Levi Z; Waked A; Maoz E; Birkenfeld S; Niv Y
Am J Gastroenterol; 2005 Nov; 100(11):2519-25. PubMed ID: 16279909
[TBL] [Abstract][Full Text] [Related]
3. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?
Hazazi R; Rozen P; Leshno M; Levi Z; Samuel Z; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2010 Feb; 31(4):523-33. PubMed ID: 19925498
[TBL] [Abstract][Full Text] [Related]
4. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
[TBL] [Abstract][Full Text] [Related]
5. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
6. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
7. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
[TBL] [Abstract][Full Text] [Related]
8. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Lieberman N; Klang S; Niv Y
Am J Gastroenterol; 2009 Apr; 104(4):933-8. PubMed ID: 19293792
[TBL] [Abstract][Full Text] [Related]
10. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
11. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
12. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
Haug U; Hundt S; Brenner H
Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood.
Rozen P; Waked A; Vilkin A; Levi Z; Niv Y
Med Sci Monit; 2006 Jun; 12(6):MT27-32. PubMed ID: 16733493
[TBL] [Abstract][Full Text] [Related]
14. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
15. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Shiratori Y
Gastroenterology; 2005 Aug; 129(2):422-8. PubMed ID: 16083699
[TBL] [Abstract][Full Text] [Related]
17. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
18. A population-based estimate of the extent of colorectal cancer screening in Ontario.
Rabeneck L; Paszat LF
Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
[TBL] [Abstract][Full Text] [Related]
19. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
[TBL] [Abstract][Full Text] [Related]
20. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
